Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0D6XT
|
|||
| Drug Name |
H3B-6527
|
|||
| Synonyms |
MBWRLLRCTIYXDW-UHFFFAOYSA-N; 1702259-66-2; UNII-4HTE364XIK; 4HTE364XIK; N-[2-[[6-[(2,6-dichloro-3,5-dimethoxyphenyl)carbamoyl-methylamino]pyrimidin-4-yl]amino]-5-(4-ethylpiperazin-1-yl)phenyl]prop-2-enamide; Eisai/H3 Biomedicine; CHEMBL3939295; SCHEMBL16659467; BDBM249396; EX-A1510; BCP17555; ZINC521836463; AKOS032960479; H3B6527; CS-5830; ACN-037543; AK684091; AC-29878; HY-100491; US9434697, 108; N-(2-((6-(3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-methylureido)pyrimidin-4-yl)amino)-5-(4-ethylpiperazin-1-yl)phenyl)acryla
Click to Show/Hide
|
|||
| Indication | Hepatocellular carcinoma [ICD-11: 2C12.02; ICD-10: C22.0; ICD-9: 155] | Phase 1 | [1] | |
| Company |
EisaiWoodcliff Lake, NJH3 Biomedicine Cambridge, MA
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C29H34Cl2N8O4
|
|||
| Canonical SMILES |
CCN1CCN(CC1)C2=CC(=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl)NC(=O)C=C
|
|||
| InChI |
1S/C29H34Cl2N8O4/c1-6-25(40)35-20-14-18(39-12-10-38(7-2)11-13-39)8-9-19(20)34-23-16-24(33-17-32-23)37(3)29(41)36-28-26(30)21(42-4)15-22(43-5)27(28)31/h6,8-9,14-17H,1,7,10-13H2,2-5H3,(H,35,40)(H,36,41)(H,32,33,34)
|
|||
| InChIKey |
MBWRLLRCTIYXDW-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1702259-66-2
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | FGFR4 messenger RNA (FGFR4 mRNA) | Target Info | Inhibitor | [1] |
| KEGG Pathway | MAPK signaling pathway | |||
| Ras signaling pathway | ||||
| Rap1 signaling pathway | ||||
| Endocytosis | ||||
| PI3K-Akt signaling pathway | ||||
| Signaling pathways regulating pluripotency of stem cells | ||||
| Regulation of actin cytoskeleton | ||||
| Panther Pathway | FGF signaling pathway | |||
| Pathway Interaction Database | FGF signaling pathway | |||
| Reactome | PI3K Cascade | |||
| PIP3 activates AKT signaling | ||||
| FGFR4 ligand binding and activation | ||||
| Constitutive Signaling by Aberrant PI3K in Cancer | ||||
| Phospholipase C-mediated cascade | ||||
| FRS-mediated FGFR4 signaling | ||||
| SHC-mediated cascade:FGFR4 | ||||
| PI-3K cascade:FGFR4 | ||||
| Negative regulation of FGFR4 signaling | ||||
| RAF/MAP kinase cascade | ||||
| WikiPathways | Regulation of Actin Cytoskeleton | |||
| Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | ||||
| PIP3 activates AKT signaling | ||||
| Signaling by FGFR | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.